Welcome to the e-CCO Library Archive!
C.difficile colonisation or infection does not appear to increase the risk of a diagnosis of IBD in the subsequent 2 years
N. Joshi*1, R. Crowson1, D. Ball2, D. Rampton1
1Queen Mary, University of London, Blizard Institute, Centre for Digestive Diseases, London, United Kingdom, 2Barts Health NHS Trust, Medical Microbiology, London, United Kingdom
D. Laukens1, H. Peeters1, P. Hindryckx1, M. De Vos1, 1Ghent University, Department of Gastroenterology, Gent, Belgium
Patient clinical characteristics at diagnosis of Ulcerative Colitis
I. Marin-Jimenez*1, C. Saro2, V. Díaz3, A. Gutierrez4, N. Borruel5, M. Gómez-García6, M. Barreiro-de Acosta7
1Hospital General Universitario Gregorio Marañón, Digestive Medicine- Gastroenterology section, Madrid, Spain, 2Hospital de Cabueñes, Digestive Department, Gijon, Spain, 3AbbVie Farmacéutica S.L.U., Inmunology, Madrid, Spain, 4Hospital General Universitario, Digestive Medicine Department, Alicante, Spain, 5Hospital Universitario Vall d´Hebrón, Gastroenterology, Barcelona, Spain, 6Hospital Universitario Virgen de las Nieves, Digestive Department, Granada, Spain, 7Hospital Clínico Universitario, Gastroenterology- Inflammatory Bowel Disease Unit, Santiago de Compostela, Spain
J. Skieceviciene1, L. Kupcinskas1, L. Jonaitis1, A. Zvirbliene1, G. Denapiene2, J. Valantinas2, M. Leja3, A. Derovs4, G. Kiudelis1, S. Schreiber5, A. Franke5, 1Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania, 2Vilnius University, Center of Hepatology, Gastroenterology and Dietetics, Vilnius, Lithuania, 3University of Latvia, Institute of Oncology, Riga, Latvia, 4Riga Stradins University, 5Internal Disease Department, Riga, Latvia, 5Christian-Albrechts-University, Institute of Clinical Molecular Biology, Kiel, Germany
Characteristics of non-responders to self-reported questionnaires in a large Inflammatory Bowel Disease cohort study
E. Multone1, J.-P. Vader1, C. Mottet2, A. Schoepfer3, N. Fournier1, B. Burnand1, P. Michetti4, V. Pittet*1
1Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland, 2Hôpital Neuchâtelois, Service of Gastroenterology, Neuchâtel, Switzerland, 3Lausanne University Hospital, Department of Gastroenterology & Hepatology, Lausanne, Switzerland, 4Clinique La Source-Beaulieu, Crohn and Colitis Center, Lausanne, Switzerland
J. Kupcinskas1, R. Steponaitiene1, G. Kiudelis1, G. Denapiene2, J. Valantinas2, L. Jonaitis1, L. Kupcinskas1, J. Skieceviciene1, 1Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania, 2Vilnius University, Center of Hepatology, Gastroenterology and Dietetics, Vilnius, Lithuania
Clostridium difficile infection in inflammatory bowel disease and non-inflammatory bowel disease patients
O. Stoica1, C. Stanciu2, C. Cojocariu1, A.-M. Singeap1, I. Girleanu1, R. Maxim1, A. Trifan*1
1University of Medicine and Pharmacy "Gr. T Popa ", Iasi, Institute of Gastroenterology and Hepatology, Iasi, Romania, 2Institute of Gastroenterology and Hepatology, Bd. Independentei, no. 1, Gastroenterology and Hepatology, Iasi, Romania
M. Waterman1, J. Knight2, J. Stempak3, K. Krishnaprasad4, I. Cleynen5, S. Vermeire6, P. Schumm7, D. McGovern8, S. Brant9, G. Radford-Smith10, M. Silverberg11, 1Rambam Health Care Campus, Department of Gastroenterology, Haifa, Israel, 2Neuroscience Research, Toronto, Canada, 3Mount Sinai Hospital, Toronto, Canada, 4Australia and New Zealand Inflammatory Bowel Disease Consortium, Australia, 5Katholieke Universiteit Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium, 6Department of Gastroenterology, University hospitals Leuven, Belgium, 7University of Chicago, United States, 8Cedars Sinai Hospital, University of California, Los Angeles, United States, 9The Johns Hopkins Hospital Division of Gastroenterology, the Meyerhoff Inflammatory Bowel Disease Center, Baltimore, United States, 10Inflammatory Bowel Diseases Research Group, Queensland Institute of Medical Research, Brisbane, Australia, 11Mount Sinai Hospital, University of Toronto, Toronto, Canada
Work disability in IBD: prevalence, severity and predictive factors.
R.-R. Huascar A.*1, C. Xavier2, S. Beatriz3, V. Mercedes4, F. Ariadna5, G. Fernando6
1Universitary Hospital of Burgos, Gastroenterology and hepatology, Burgos, Spain, 2Corporació sanitaria universitaria Parc Taulí, Servei aparell digestiu, Sabadel, Spain, 3Hospital Universitary of Burgos, Gastroenterology and Hepatology, Burgos, Spain, 4InstituTO de Salud Carlos III, Gastroenterology, Madrid, Spain, 5Fundación Universitaria de Bages, Gastroenterology, Barcelona, Spain, 6Hospital clínico universitario de Zaragoza, Gastroenterologia, Zaragoza, Spain
B. Kabakchiev1, A. Tyler1, J. Stempak1, M. Silverberg2, 1Mount Sinai Hospital, SLRI, Toronto, Canada, 2Mount Sinai Hospital, Gastroenterology, Toronto, Canada
The SOLE Survey: Disease related concerns of a large cohort of Italian patients with active Crohn's Disease
A. Armuzzi*1, G. Riegler2, F. Furfaro3, M. Baldoni4, F. Costa5, M. Fortuna6, M. Vecchi7, G. Iaquinto8, P. Paese9, C. Papi10, F. Bossa11, V. Tornatore12, F. Rizzello13
1Complesso Integrato Columbus, Università Cattolica del Sacro Cuore, IBD Unit, Roma, Italy, 2Seconda Università di Napoli, Gastroenterology, Napoli, Italy, 3Ospedale Universitario L. Sacco, Gastroenterology, Milano, Italy, 4Università di Perugia, Gastroenterology, Perugia, Italy, 5Azienda Ospedaliero-Universitaria Pisana, Gastroenterology, Pisa, Italy, 6Ospedale Sacro Cuore Don Calabria, Gastroenterology, Negrar-Verona, Italy, 7Irccs Policlinico San Donato, Gastroenterology, Milano, Italy, 8Azienda Ospedaliera San Giuseppe Moscati, Gastroenterology, Avellino, Italy, 9Azienda Ospedaliera di Cosenza, Gastroenterology, Cosenza, Italy, 10Azienda Ospedaliera San Filippo Neri, Gastroenterology, Roma, Italy, 11Ospedale Casa Sollievo della Sofferenza, Gastroenterology, San Giovanni Rotondo, Italy, 12AbbVie srl, Medical Affairs, Campoverde, Italy, 13Policlinico S. Orsola-Malpighi, Gastroenterology, Bologna, Italy
N. Maharshak1, M. Ellermann1, R. Gharaibeh2, W. Sha2, E. Perez-Chanona3, K. Whitehead1, C. Jobin1, A. Fodor2, S.E. Plevy1, R.B. Sartor1, 1University of North Carolina, Department of Immunology and Microbiology, Chapel Hill, United States, 2University of North Carolina, Department of Bioinformatics and Genomics, Charlotte, United States, 3University of North Carolina, Department of Pharmacology, Chapel Hill, United States
Inflammatory Bowel Disease and psychological status: Determinants and social consequences
P. Bertomoro*, M. G. Vettorato, F. Simonetti, L. Dall’angelo, G. Brogiato, A. Rigo, R. D’Incà, G. C. Sturniolo
Policlinico Universitario di Padova, Gastroenterologia, Padova, Italy
K. Fukuda1, Y. Fujita1, 1St. Luke's international hospital, Gastroenterology, Tokyo, Japan
Current views and concerns of European UC patients based on an online survey
R. Hofmann*1, X. Guillaume2
1Tillotts Pharma, Medical Affairs, Rheinfelden, Switzerland, 2Kantar Health , Research, Montrouge, France
H. Vebø1, C. Casen1, D. Vangen1, F.T. Hegge1, G. Perminov2, P. Ricanec3, M.H. Vatn4, 1Genetic Analysis AS, Oslo, Norway, 2Oslo University Hospital, Department of pediatrics, Oslo, Norway, 3Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 4Oslo University Hospital, Department of Medicine, Oslo, Norway
Budget impact analysis of introducing biosimilar infliximab for the treatment of gastro intestinal disorders in five European countries
A. Jha*1, W. Dunlop1, A. Upton2
1Mundipharma International Ltd., Market Access, Cambridge, United Kingdom, 2Abacus International, Health Economics and Outcomes Research, Bicester, United Kingdom
C. Landman1, A. Besse1, M.-A. Maubert1, L. Brot1, L. Humbert1, J. Cosnes2, L. Beaugerie2, G. Trugnan1, H. Sokol1, D. Rainteau1, Q. Elodie1, P. Seksik1, 1St Antoine Hospital, Inserm Erl U 1057, UMR 7203, Paris, France, 2St Antoine Hospital, Gastroenterology, Paris, France
Therapeutic management of Ulcerative Colitis at gastroenterology units in Spain
I. Marin-Jimenez*1, C. Saro2, V. Díaz3, A. Gutierrez4, N. Borruel5, M. Gómez-García6, M. Barreiro-de Acosta7
1Hospital General Universitario Gregorio Marañón, Digestive Medicine- Gastroenterology section, Madrid, Spain, 2Hospital de Cabueñes, Digestive Department, Gijon, Spain, 3AbbVie Farmacéutica S.L.U., Inmunology, Madrid, Spain, 4Hospital General Universitario, Digestive Medicine Department, Alicante, Spain, 5Hospital Universitario Vall d´Hebrón, Gastroenterology, Barcelona, Spain, 6Hospital Universitario Virgen de las Nieves, Digestive Department, Granada, Spain, 7Hospital Clínico Universitario, Gastroenterology- Inflammatory Bowel Disease Unit, Santiago de Compostela, Spain
A. Banaszkiewicz1, A. Gawronska1, J. Kadzielska2, I. Lazowska-Przeorek1, K. Karolewska-Bochenek1, P. Obuch-Woszczatynski2, D. Wultanska2, H. Pituch2, A. Radzikowski1, 1Medical University of Warsaw, Dept of Paediatric Gastroenterology and Nutrition, Warsaw, Poland, 2Medical University of Warsaw, Dept of Medical Microbiology, Warsaw, Poland